The UK and US have finalized a important bilateral deal that will ensure no tariffs on British medicine shipments entering the US market.
Key Provisions of the Deal
In exchange for the tariff guarantee, the UK has pledged to increase spending on drugs through the public health system. This move ensures that tariffs on these key products will remain at nothing for a period of three years.
This development follows earlier statements to significantly raise import taxes on branded pharmaceutical products, with increases discussed up to 100%.
"This arrangement between the Britain bolsters the international landscape for innovative medicines and establishes long-overdue fairness to American-British drug exports," a statement declared.
Economic Importance
Pharmaceuticals are one of the the United Kingdom's biggest export categories to the US, which is clearly the primary destination for large UK drugmakers.
Trade data reveal that in the 12 months to the end of the third quarter, the UK exported drugs totaling billions to the US. This value made up a significant portion of British export trade in that span.
"This guarantee safeguards work, boosts capital expenditure and sets the stage for the UK to establish itself as a international leader for medical research," the Business and Trade Secretary stated.
Detailed British Pledges
The deal involves several specific pledges from the British government:
- Price Threshold Increase: The UK will raise the affordability limit at which it deems new therapies to be unaffordable by 25%.
- Increased NHS Spending: There is a goal to raise overall health service expenditure on drugs from 0.3 percent of the national economy to 0.6% over the next decade.
- Payback Limit: The percentage manufacturers must pay back to the NHS to prevent overspending will be capped at 15%. Previously, repayments topped 20%.
Broader Context
The pact follows a ongoing row between the drug companies and the British authorities over drug pricing and NHS adoption.
This friction were exacerbated by arguments that US consumers were paying significantly more for the identical medicines than people in the UK and Europe.
In recent months, several major manufacturing plans in the UK have been delayed or scrapped, while substantial funding commitments have been announced toward projects in the United States.
The Science Minister stated that the NHS needed to invest a greater share on drugs, noting that its expenditure on drugs had declined as a proportion of its resources over the last ten years.
